Suggestions
Idioma
metricas
Publish in this journal
Guide for authors
Searcher
Journal Information
Vol. 61. Issue 3.
Pages 163-262 (July - September 2026)
Cite
Cite
Share
Download PDF
More article options
Visits
6992
Vol. 61. Issue 3.
Pages 163-262 (July - September 2026)
Artículo original
Eficacia y seguridad del uso de citisina en fumadores con enfermedad cardiovascular: un estudio observacional
Efficacy and safety of cytisine use in smokers with cardiovascular disease: An observational study
Visits
6992
Marisol Bravo-Amaro
Corresponding author
maria.sol.bravo.amaro@sergas.es

Autor para correspondencia.
, Rafael Cobas-Paz, Dámaris Carballeira-Puentes, Concepción Abreu-Pazó, Iria Sánchez-Fernández, Andrés Íñiguez-Romo
Servicio de Cardiología, Hospital Universitario Álvaro Cunqueiro, Vigo, Pontevedra, España
Related content
Antonio García-Quintana, Marta López Pérez, Victoria Piro Mastracchio
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Resumen
Introducción y objetivos

El tabaquismo es un factor de riesgo para la enfermedad cardiovascular (ECV). Aunque el cese tabáquico es clave en la prevención secundaria cardiovascular, el uso de citisina como terapia farmacológica sigue siendo limitado en los pacientes con ECV por falta de evidencia específica. El objetivo de este estudio fue evaluar la eficacia y el perfil de seguridad de la citisina en los pacientes con ECV estable, al menos 30 días después de un síndrome coronario agudo.

Métodos

Se realizó un estudio observacional prospectivo en un centro hospitalario de nivel terciario entre 2022 y 2024. Se incluyó a 80 pacientes de forma consecutiva con ECV estable al menos 30 días después del síndrome coronario agudo, fumadores activos y con intención de cesación, que recibieron citisina durante 25 días. Se evaluó el cese tabáquico mediante entrevista clínica a un mes y seguimiento telefónico a largo plazo. Se registraron los efectos adversos.

Resultados

A los 30 días del inicio del tratamiento, el 62,5% de los pacientes había cesado el consumo de tabaco; a los 15 meses, el 52,5% mantenía la abstinencia. Se registraron efectos adversos en el 7,5% de los pacientes, en su mayoría leves. Se observaron 2 eventos graves, no atribuibles directamente al tratamiento.

Conclusiones

La citisina mostró una eficacia y seguridad prometedoras en los pacientes con ECV estable. Estos hallazgos apoyan su uso como herramienta terapéutica en programas de cesación tabáquica, aunque se requieren estudios adicionales más robustos.

Palabras clave:
Citisina
Enfermedad cardiovascular
Cesación tabáquica
Seguridad farmacológica
Efectividad farmacológica
Abreviaturas:
ECV
SCA
Abstract
Introduction and objectives

Smoking is a major risk factor for cardiovascular disease (CVD). Although smoking cessation is key in secondary cardiovascular prevention, the use of cytisine as a pharmacological aid remains limited in CVD patients due to a lack of specific evidence. This study aimed to assess the efficacy and safety profile of cytisine in patients with stable CVD, at least 30 days after an acute coronary syndrome.

Methods

A prospective observational study was conducted at between 2022 and 2024 in a tertiary-level hospital. 80 consecutive patients with stable CVD at least 30 days post- acute coronary syndrome, active smokers with a willingness to quit, were treated with cytisine for 25 days. Smoking cessation was assessed through a clinical interview at 1 month and long-term follow-up via telephone. Adverse events were recorded.

Results

At 30 days, 62.5% of patients had quit smoking; at 15 months, 52.5% remained abstinent. Adverse events were reported in 7.5% of participants, mostly mild. Two serious adverse events occurred but were not directly attributable to the treatment.

Conclusions

Cytisine demonstrated promising efficacy and safety in patients with stable CVD. These findings support its potential role as a therapeutic tool in smoking cessation programmes, although further robust studies are warranted.

Keywords:
Cytisine
Cardiovascular disease
Smoking cessation
Drug safety
Pharmacological effectiveness

Article

These are the options to access the full texts of the publication REC: CardioClinics
Member
Socios SEC
Use datos de acceso a SEC en el menú Acceder.
Si es socio de la Sociedad Española de Cardiología y no puede acceder con sus claves, escriba a rec@cardioclinics.org.
Members of SEC
Use the Society's website login and password here.
If you are member of SEC and you have some problems with your login data, please contact with rec@cardioclinics.org.
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to
REC: CardioClinics
Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
Email
Bibliografía
[1]
T.A. Gaziano.
Consideraciones generales de las enfermedades cardiovasculares.
Tratado de Cardiología, 11ª ed., pp. 1-18
[2]
R. Doll, R. Peto, J. Boreham, I. Sutherland.
Mortality in relation to smoking: 50 years’ observations on male British doctors.
[3]
E. Prescott, M. Hippe, P. Schnohr, H.O. Hein, J. Vestbo.
Smoking and risk of myocardial infarction in women and men: Longitudinal population study.
BMJ, 316 (1998), pp. 1043-1047
[4]
J.H. Cole, J.I. Miller, L.S. Sperling, W.S. Weintraub.
Long-term follow-up of coronary artery disease presenting in young adults.
J Am Coll Cardiol, 41 (2003), pp. 521-528
[5]
A. Lloyd, L. Steele, J. Fotheringham, et al.
Pronounced increase in risk of acute ST-segment elevation myocardial infarction in younger smokers.
[6]
R.R. Huxley, M. Woodward.
Cigarette smoking as a risk factor for coronary heart disease in women compared with men: A systematic review and meta-analysis of prospective cohort studies.
Lancet, 378 (2011), pp. 1297-1305
[7]
R. Gupta, S. Gupta, S. Sharma, D.N. Sinha, R. Mehrotra.
Risk of Coronary Heart Disease Among Smokeless Tobacco Users: Results of Systematic Review and Meta-Analysis of Global Data.
Nicotine Tob Res, 21 (2019), pp. 25-31
[8]
X. Lv, J. Sun, Y. Bi, et al.
Risk of all-cause mortality and cardiovascular disease associated with secondhand smoke exposure: A systematic review and meta-analysis.
Int J Cardiol, 199 (2015), pp. 106-115
[9]
A. Hackshaw, J.K. Morris, S. Boniface, J.L. Tang, D. Milenković.
Low cigarette consumption and risk of coronary heart disease and stroke: Meta-analysis of 141 cohort studies in 55 study reports.
BMJ., 360 (2018), pp. j5855
[10]
K. Kotseva, G. de Backer, D. de Bacquer, EUROASPIRE Investigators, et al.
Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry.
Eur J Prev Cardiol, 26 (2019), pp. 824-835
[11]
N.A. Rigotti, C. Clair, M.R. Munafò, L.F. Stead.
Interventions for smoking cessation in hospitalised patients.
Cochrane Database Syst Rev, 5 (2012),
[12]
J.A. Critchley, S. Capewell.
Mortality Risk Reduction Associated With Smoking Cessation in Patients With Coronary Heart Disease: A Systematic Review.
[13]
N.R. Anthonisen, M.A. Skeans, R.A. Wise, et al.
The Effects of a Smoking Cessation Intervention on 14.5-Year Mortality.
[14]
Ridker P.M. Libby P. Buring J.E. In: Braunwald (ed.), Tratado de Cardiología. 11.ª. Barcelona’ 2019. 876-909.
[15]
F.L.J. Visseren, F. Mach, Y.M. Smulders, ESC National Cardiac Societies; ESC Scientific Document Group, et al.
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC).
Eur Heart J, 42 (2021), pp. 3227-3337
[16]
J. Hartmann-Boyce, S.C. Chepkin, W. Ye, C. Bullen, T. Lancaster.
Nicotine replacement therapy versus control for smoking cessation.
Cochrane Database Syst Rev, 5 (2018),
[17]
J.R. Hughes, L.F. Stead, J. Hartmann-Boyce, K. Cahill, T. Lancaster.
Antidepressants for smoking cessation.
Cochrane Database Syst Rev, 2014 (2014),
[18]
K. Cahill, N. Lindson-Hawley, K.H. Thomas, T.R. Fanshawe, T. Lancaster.
Nicotine receptor partial agonists for smoking cessation.
Cochrane Database Syst Rev, 2016 (2016),
[19]
CIMA. Ficha tecnica todacitan 1,5mg comprimidos EFG [consultado 17 Jul 2025] Disponible en: https://cima.aemps.es/cima/dochtml/ft/83407/FT_83407.html#4.3
[20]
P. Pozzi, R. Boffi, C. Veronese, et al.
Cytisine as a smoking cessation aid: Preliminary observations with a modified therapeutic scheme in real life.
Tumori, 110 (2024), pp. 124-131
[21]
T. Erika, C. Sofia, T. Alessandro, et al.
Cytisine for smoking cessation in hospitalised smokers with cardiovascular diseases: an observational study.
Intern Emerg Med, 20 (2025), pp. 817-828
[22]
L. Daza-Cazana.
Test de Fagerstrom para evaluar la dependencia física a la nicotina del tabaco: Instrucciones para su aplicación, recomendaciones para brindar ayuda y recomendaciones para pacientes.
MED-FMENT Salud Pública en Acción, 5 (2024), pp. e1-e8
[23]
Good pharmacovigilance practices (GVP) | European Medicines Agency (EMA), (2012),
[24]
J.A. Critchley, S. Capewell.
WITHDRAWN: Smoking cessation for the secondary prevention of coronary heart disease.
Cochrane Database Syst Rev, 2012 (2012),
[25]
A.D. Wu, N. Lindson, J. Hartmann-Boyce, et al.
Smoking cessation for secondary prevention of cardiovascular disease.
Cochrane Database Syst Rev, 8 (2022),
[26]
N.L. Benowitz, A. Pipe, R. West, et al.
Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers: A Randomized Clinical Trial.
JAMA Intern Med, 178 (2018), pp. 622-631
[27]
S. Ofori, C. Lu, O.O. Olasupo, et al.
Cytisine for smoking cessation: A systematic review and meta-analysis.
Drug Alcohol Depend, 251 (2023),
[28]
O. De Santi, M. Orellana, C.A. di Niro, V. Greco.
Evaluation of the effectiveness of cytisine for the treatment of smoking cessation: A systematic review and meta-analysis.
Addiction, 119 (2024), pp. 649-663
[29]
J. Leaviss, W. Sullivan, S. Ren, et al.
What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? A systematic review and economic evaluation.
Health Technol Assess, 18 (2014), pp. 1-120
[30]
N.A. Rigotti, N.L. Benowitz, J. Prochaska, et al.
Cytisinicline for Smoking Cessation: A Randomized Clinical Trial.
JAMA, 330 (2023), pp. 152-160
[31]
U. Pastorino, V. Ladisa, S. Trussardo, et al.
Cytisine Therapy Improved Smoking Cessation in the Randomized Screening and Multiple Intervention on Lung Epidemics Lung Cancer Screening Trial.
J Thorac Oncol, 17 (2022), pp. 1276-1286
[32]
B. Ramotowski, A. Budaj.
Is cytisine contraindicated in smoking patients with coronary artery disease after percutaneous coronary intervention?.
Kardiol Pol, 79 (2021), pp. 813-819
[33]
E.V. Radchenko, Р.Е Владимировна, O.A. Sykhovskaya, et al.
Network meta-analysis: A comparison of effectiveness and safety of partial agonists of nicotinic acetylcholine receptors varenicline and cytisine for smoking cessation.
Clin Pharmacol Ther, 16 (2018), pp. 19-32
Idiomas
REC: CardioClinics
Article options
Tools